Igeneon's IGN101 Vaccine Prolongs Survival of Cancer Patients
Vienna - The anti-cancer vaccine IGN101 of Austrian Igeneon AG has made an important advance in its clinical development. Results of a phase II trial show a statistically significant survival prolongation in the group of patients with metastatic rectal cancer. Furthermore vaccinations with IGN101 were well tolerated in all indications.
“To have completed this placebo-controlled phase II trial with IGN101 is a major milestone in the development of our lead product candidate,” said Dr. Manfred Ruediger, CEO of Igeneon. Based on the results of this trial, Igeneon is designing a pivotal phase II/III trial with IGN101 to confirm the findings. IGN101 is an active cancer vaccine consisting of the murine monoclonal antibody edrecolomab as vaccine antigen which is designed to prevent or delay the formation of metastases. It is also currently tested in a pivotal phase II/III trial in the second indication, non-small cell lung cancer.
In phase I and phase II trials IGN101 has been shown to induce an immune response, even when administered under concomitant chemotherapy. Igeneon's second most advanced product candidate, the IGN311 monoclonal antibody targeting Lewis Y-positive cancer cells, is expected to complete a phase I trial in 2004.